Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech efalizumab is Raptiva

Executive Summary

Genentech/Xoma change name of psoriasis agent Xanelim to Raptiva in order to "limit potential confusion" with Idec's non-Hodgkin's lymphoma agent Zevalin. The efalizumab BLA filing was delayed after a pharmacokinetic study comparing Xoma-produced study drug to Genentech-produced commercial drug was not found to be comparable (1"The Pink Sheet" April 8, In Brief). Genentech hopes to file the BLA before the end of 2002...

You may also be interested in...

Genentech/Xoma Xanelim BLA delay

Genentech/Xoma's Xanelim (efalizumab) BLA filing will be delayed beyond summer 2002, companies announce April 5. A pharmacokinetic study comparing Genentech-produced to Xoma-produced drug did not achieve statistical definition of comparability. Genentech had projected a summer 2002 BLA filing for the psoriasis therapy (1"The Pink Sheet" Jan. 21, p. 32)...

Health And Wellness Trademark Review 2 March, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations

Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts